Latest News - Stryker Corporation
Top Corporates Hub
Stryker Corporation
Stryker (SYK) Tests Its Valuation After Sonopet 3 Clearance
23.10.2026 15:16
Stryker (SYK) just received 510(k) clearance from the U.S. Food and Drug Administration for Sonopet 3, a new ultrasonic bone and soft tissue removal platform shaped by extensive surgeon feedback. For context, Stryker’s recent 1 month share price return of 11.63% and 7 day move of 4.72% have come after a tougher patch, with the stock down 7.02% over 3 months and its 1 year total shareholder return declining 18.95%. Meanwhile, the 3 year and 5 year total shareholder returns of 22.32% and 20.59%...
Stryker (SYK) Stock May Trade At A Discount Despite FDA Clearance
23.10.2026 03:18
Stryker has had a mixed run, with the share price up 22.3% over three years but still showing declines over the past year. This puts fresh focus on whether the current US$307.08 level lines up with the cash the business can generate. With new products, fresh partnerships and legal scrutiny all in play, the question for anyone looking at the stock is how those moving parts feed into its underlying cash flow story. The 22.3% gain over three years means a holder today is looking at a stock...
PAHC or SYK: Which Is the Better Value Stock Right Now?
21.10.2026 14:40
PAHC vs. SYK: Which Stock Is the Better Value Option?
Stryker's Sonopet 3 Secures FDA Clearance to Improve Surgical Accuracy
21.10.2026 11:14
SYK's Sonopet 3 secures FDA clearance, promising enhanced surgical precision and efficiency, with a full commercial launch expected later this fall.
What Is Stryker (SYK) Really Getting From Its $400 Million Robotics Deal?
15.10.2026 16:16
Stryker (NYSE:SYK) agreed to invest US$400m in CMR Surgical in a deal focused on soft-tissue robotic surgery. The agreement grants Stryker exclusive U.S. rights to commercialize CMR's Versius robotic surgery platform. Stryker also secured an exclusive option to acquire CMR Surgical, extending its reach beyond orthopedics and MedSurg. The US$400m CMR Surgical deal, which includes U.S. Versius rights and an acquisition option, is only one piece of the Stryker story. We have also flagged 2...
AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist
15.10.2026 13:27
AngioDynamics, Inc. stock analysis: AlphaVac, Auryon, NanoKnife growth vs execution risk and margin swings. Click for this updated look at ANGO prospects.
Stryker Announces $400 Million Investment in CMR Surgical With Option for Full Acquisition
12.10.2026 12:30
Stryker (NYSE:SYK) has announced a strategic partnership with UK-based medical robotics company CMR Surgical, including an approximately $400 million (£300 million) preferred equity investment and an exclusive option to acquire the business in the future. The agreement will give Stryker an opportunity to expand its presence in the soft-tissue robotic surgery market while establishing a commercial relationship around CMR Surgical’s Versius robotic surgery platform.
Stryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
12.10.2026 12:00
Portage, Mich., USA and Cambridge, England, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Strategic alliance combines CMR Surgical’s established platform and robotics expertise with Stryker’s scale, customer relationships and commercial reach to accelerate growth of the Versius Surgical Robotic portfolio Stryker will make an approximately $400 million (£300 million) preferred equity investment in CMR Surgical to support future innovation and global commercialization of the Versius portfolio, subject to cust
BTIG Maintains Buy on Stryker, Lowers Price Target to $316
12.10.2026 06:09
BTIG analyst Ryan Zimmerman maintains Stryker (NYSE:SYK) with a Buy and lowers the price target from $358 to $316.
1 Profitable Stock on Our Watchlist and 2 We Ignore
08.10.2026 11:44
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies — as Jeff Bezos said, “Your margin is my opportunity”.
Tilray Brands, Inc. (TLRY) Reports Q1 Loss, Misses Revenue Estimates
08.10.2026 11:10
Tilray Brands (TLRY) delivered earnings and revenue surprises of -68.42% and -1.98%, respectively, for the quarter ended August 2026. Do the numbers hold clues to what lies ahead for the stock?
Stryker (NYSE:SYK) Balances Dividend Quality and Profitability for Income Investors
08.10.2026 08:31
Stryker (SYK) scores 7/10 for dividends with strong profitability, low payout ratio, and steady growth—a quality income pick balancing yield and safety.
Stryker (SYK) Stock Could Be Cheap After Its 26% Slide
08.10.2026 04:31
Stryker has seen its share price slide over the past year, and a planned CEO transition has added a fresh storyline for investors to absorb. The question now is whether the current US$275.40 price tag is aligned with the cash flows the business is expected to generate. The stock has fallen 25.8% over the past year, which puts a sharper focus on whether that decline has brought the valuation closer to what its cash flows can justify. The planned handover from long-serving CEO Kevin Lobo to...
Barclays Initiates Coverage On Stryker with Overweight Rating, Announces Price Target of $375
07.10.2026 09:13
Barclays analyst Christopher Pasquale initiates coverage on Stryker (NYSE:SYK) with a Overweight rating and announces Price Target of $375.
Stryker (SYK) vs Boston Scientific (BSX): Which is a Better Stock to Buy?
07.10.2026 00:00
Stryker Corporation (NYSE:SYK) traded at around $280 on October 6, 22.75% lower over twelve months. Boston Scientific Corporation (NYSE:BSX) traded near $42 over the same session, down 55.79% across the year and within sixty cents of its 52-week low. Boston Scientific reports the better margins of the two, which makes the larger fall the thing […]
Stryker: This Dividend Aristocrat Is Finally Cheap Again
05.10.2026 07:30
Stryker is upgraded to 'Strong Buy' after a significant price pullback to $275, offering compelling value relative to historical valuation. Learn more about SYK stock here.
Stryker (SYK) Expanded Its Foot And Ankle Portfolio
22.09.2026 10:14
Stryker (NYSE:SYK) announced new Foot & Ankle portfolio updates, including expanded Prophecy Surgical Planning, at a major industry meeting. The company introduced the Hoffmann LRF smartHEX system, aimed at limb reconstruction and patient connectivity in complex cases. Expanded planning tools and patient specific technologies are intended to support surgeon decision making in ankle replacement procedures. The Prophecy Surgical Planning expansion and Hoffmann LRF smartHEX launch sit alongside...
Stryker (SYK) Expanded Its Foot And Ankle Portfolio
22.09.2026 10:14
Stryker (NYSE:SYK) announced new Foot & Ankle portfolio updates, including expanded Prophecy Surgical Planning, at a major industry meeting. The company introduced the Hoffmann LRF smartHEX system, aimed at limb reconstruction and patient connectivity in complex cases. Expanded planning tools and patient specific technologies are intended to support surgeon decision making in ankle replacement procedures. The Prophecy Surgical Planning expansion and Hoffmann LRF smartHEX launch sit alongside...
Canaccord Genuity Maintains Buy on Stryker, Lowers Price Target to $385
18.09.2026 08:35
Canaccord Genuity analyst Kyle Rose maintains Stryker (NYSE:SYK) with a Buy and lowers the price target from $400 to $385.
Stryker stock falls on slower peripheral vascular, hip sales
10.09.2026 12:06
CFO Preston Wells said at a healthcare conference that the company is still working through supply issues in its peripheral vascular business and had fewer hip sales than expected so far this quarter.